# OnCo record ala-101 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ala-101/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ala-101" ;
  schema:name "ALA-101"@en ;
  schema:alternateName "CAR19-iNKT"@en ;
  schema:description "ALA-101 is an experimental allogeneic CAR-iNKT cell therapy from Arovella Therapeutics, in phase 1 trials for CD19-positive B-cell lymphoma, CD19-positive leukaemia and non-Hodgkin lymphoma."@en ;
  schema:url <https://onco.cc/drugs/ala-101/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.arovella.com/ala-101-car19-inkt>, <https://www.arovella.com/ala-101-car19-inkt>, <https://clinicaltrials.gov/api/v2/studies/NCT07518329>, <https://clinicaltrials.gov/search?intr=ALA-101> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Allogeneic CAR-iNKT cell therapy" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/arovella-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07518329/> .